Cryopreserved Hair Follicles for Disease and Cell Replacement

Acorn Biolabs Inc.100 enrolled

Overview

To explore the application of cells expanded from plucked hair follicles after collection, transport, and cryopreservation, in disease modeling and cell-based therapies.

Hair Follicles collected and transported in Acorn's proprietary transport media can serve has therapeutic starting materials for future cell-based therapeutics. This study is to characterize primary cell outgrowth, functional stem cell generation and induced pluripotent stem cell line(s) from primary outgrowth(s) as well as evaluate and characterize differentiation of stem cell lines into functional cell types required for various disease states and cell-based application(s).

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Diabetes Mellitus Sport Injury Injury Traumatic

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Gender: Male or Female. * Age: ≥18 and ≤80 years. * Language proficiency: Able to read and understand English. * Informed consent: Willing to provide written, informed consent to participate in all study activities. Exclusion Criteria: * Scalp/Hair Disorders: Subjects diagnosed with active scalp infections or inflammatory skin conditions. * Systemic Conditions: Subjects with chronic illnesses, such as autoimmune diseases or diabetes, that may impact scalp health or wound healing. * Medications: Subjects on immunosuppressants, steroids, or other medications associated with hair loss.

Locations (1)

Acorn Biolabs

Toronto, Quebec, Canada

RECRUITING

Outcomes

Primary Outcomes

Characterize primary cellular outgrowth(s)

10 hair follicles will be placed in a tissue culture plate per participants. Over the course of 30 days, the outgrowth percentage (the number of outgrowths present out of 10 will be monitored and the confluency (percent of cells present in relation to surface area) will be noted for each participant.

Time frame: 30 days

Evaluate functional stem cell generation and induced pluripotent stem cell line(s) from primary outgrowth(s)

1 million keratinocytes will be taken for reprogramming for each participant. The number of iPS colonies observed on day 21 will be noted, resulting in a reprogramming efficiency score.

Time frame: 21 days

Evaluate and characterize differentiation of stem cell lines into functional cell types required for various disease states and cell-based application(s)

iPS cell lines which have been confirmed to be pluripotent will be differentiated into pancreatic progenitor cells and hematopoietic stem cells. The cells will be analyzed using FLOW cytometry and the percentage of double positive cells will be noted for each participant. This will be repeated for multiple pathways such as the hematopoietic and endothelial lineage(s).

Time frame: 30 days

Central Contacts

Drew Taylor, MSc, PhD

CONTACT

226-929-8476 info@acorn.me

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.